|
GRB10 |
growth factor receptor bound protein 10 |
- Signaling by SCF-KIT
- IRS activation
- Signal attenuation
- Insulin receptor signalling cascade
- RET signaling
- FLT3 Signaling
- Response of EIF2AK1 (HRI) to heme deficiency
|
|
|
|
GRB2 |
growth factor receptor bound protein 2 |
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
|
|
GRIN2A |
glutamate ionotropic receptor NMDA type subunit 2A |
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- MECP2 regulates neuronal receptors and channels
- Assembly and cell surface presentation of NMDA receptors
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Glutamic acid
- Glycine
- Tramadol
- Enflurane
- Atomoxetine
- Pentobarbital
- Methadone
- Secobarbital
- Meperidine
- Dextropropoxyphene
- Acamprosate
- Donepezil
- Guaifenesin
- Felbamate
- Memantine
- Halothane
- Phenobarbital
- Aripiprazole
- Tenocyclidine
- Prasterone
- Milnacipran
- Acetylcysteine
- Ketobemidone
- Gavestinel
- Magnesium acetate tetrahydrate
- Magnesium carbonate
- Esketamine
- Fluciclovine (18F)
|
|
|
GRIN2B |
glutamate ionotropic receptor NMDA type subunit 2B |
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- MECP2 regulates neuronal receptors and channels
- Activated NTRK2 signals through FYN
- Assembly and cell surface presentation of NMDA receptors
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Glutamic acid
- Tramadol
- Enflurane
- Atomoxetine
- Pentobarbital
- Methadone
- Secobarbital
- Meperidine
- Haloperidol
- Dextropropoxyphene
- Acamprosate
- Donepezil
- Guaifenesin
- Felbamate
- Memantine
- Phenobarbital
- Aripiprazole
- Tenocyclidine
- Prasterone
- Taurine
- Milnacipran
- EVT-101
- Lumateperone
- Acetylcysteine
- Ketobemidone
- Gavestinel
- Ifenprodil
- Magnesium acetate tetrahydrate
- Magnesium carbonate
- Esketamine
- Esketamine
- Fluciclovine (18F)
|
|
|
GRK2 |
G protein-coupled receptor kinase 2 |
- Calmodulin induced events
- G alpha (q) signalling events
- G alpha (s) signalling events
- Activation of SMO
- Activation of SMO
- Cargo recognition for clathrin-mediated endocytosis
|
|
|
|
GTF2I |
general transcription factor IIi |
|
|
|
|
GUCY2C |
guanylate cyclase 2C |
- Digestion
- Intestinal infectious diseases
|
|
|
|
HDAC3 |
histone deacetylase 3 |
- p75NTR negatively regulates cell cycle via SC1
- PPARA activates gene expression
- PPARA activates gene expression
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Association of TriC/CCT with target proteins during biosynthesis
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Loss of MECP2 binding ability to the NCoR/SMRT complex
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- HCMV Early Events
- STAT3 nuclear events downstream of ALK signaling
- Cytoprotection by HMOX1
- Heme signaling
- Heme signaling
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
- Valproic acid
- Decitabine
- Vorinostat
- Vorinostat
- Belinostat
- Pracinostat
- Romidepsin
- Panobinostat
- Phenylbutyric acid
- Mocetinostat
- Entinostat
- Abexinostat
- Givinostat
- Pyroxamide
|
|
|
HEMGN |
hemogen |
|
|
|
|
HLA-A |
major histocompatibility complex, class I, A |
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Nef mediated downregulation of MHC class I complex cell surface expression
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Interferon gamma signaling
- E3 ubiquitin ligases ubiquitinate target proteins
- Interferon alpha/beta signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- 3-Indolebutyric Acid
- Nelipepimut-S
- Nelipepimut-S
- Coccidioides immitis spherule
- Coccidioides immitis spherule
|
|
|
HLA-B |
major histocompatibility complex, class I, B |
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- DAP12 interactions
- Neutrophil degranulation
- Interferon gamma signaling
- Interferon alpha/beta signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- Abacavir
- N-Formylmethionine
- Coccidioides immitis spherule
|
|
|
HNF1A |
HNF1 homeobox A |
- Regulation of gene expression in beta cells
|
|
- Maturity onset diabetes of the young (MODY)
|
|
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
- SUMOylation of RNA binding proteins
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
- HCMV Late Events
|
- Artenimol
- Phenethyl Isothiocyanate
|
|
|
HRAS |
HRas proto-oncogene, GTPase |
- SOS-mediated signalling
- Activation of RAS in B cells
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Signalling to RAS
- p38MAPK events
- p38MAPK events
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- FCERI mediated MAPK activation
- NCAM signaling for neurite out-growth
- EPHB-mediated forward signaling
- Ras activation upon Ca2+ influx through NMDA receptor
- VEGFR2 mediated cell proliferation
- CD209 (DC-SIGN) signaling
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- Regulation of RAS by GAPs
- RAF activation
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- RAS signaling downstream of NF1 loss-of-function variants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Insulin receptor signalling cascade
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAS signaling
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Estrogen-stimulated signaling through PRKCZ
- RAS processing
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by RAS GAP mutants
- Signaling by RAS GTPase mutants
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
- N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
- Ursolic acid
|
- Penile cancer
- Cervical cancer
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Hepatocellular carcinoma
- Thyroid cancer
- Squamous cell carcinoma
- Bladder cancer
|
|
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Regulation of necroptotic cell death
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- RHOBTB2 GTPase cycle
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Potential therapeutics for SARS
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Assembly and release of respiratory syncytial virus (RSV) virions
- Respiratory syncytial virus genome replication
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- CCT-018159
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Polaprezinc
- Alvespimycin
|
|
|
IGF1R |
insulin like growth factor 1 receptor |
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- IRS-related events triggered by IGF1R
- SHC-related events triggered by IGF1R
- Extra-nuclear estrogen signaling
- Respiratory syncytial virus (RSV) attachment and entry
|
- Insulin human
- Insulin lispro
- Insulin glargine
- Insulin pork
- Mecasermin
- Insulin aspart
- Insulin detemir
- Insulin glulisine
- Phosphoaminophosphonic Acid-Adenylate Ester
- ATL1101
- XL228
- rhIGFBP-3
- Linsitinib
- Teprotumumab
- (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
- 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
- Nandrolone decanoate
- Somatrem
- Insulin beef
- Insulin degludec
- Insulin argine
- Insulin peglispro
- Insulin tregopil
- Dalotuzumab
- Cixutumumab
- Brigatinib
- Mecasermin rinfabate
- BMS-754807
- KW-2450 free base
|
- Synovial sarcoma
- Malignant pleural mesothelioma
|
|
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- Regulation of NF-kappa B signaling
- PKR-mediated signaling
- SLC15A4:TASL-dependent IRF5 activation
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Modulation of host responses by IFN-stimulated genes
|
- Mesalazine
- Acetylsalicylic acid
- Auranofin
- Arsenic trioxide
- MLN0415
- Acetylcysteine
- Ertiprotafib
- Fostamatinib
|
|
|
IKBKG |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- SUMOylation of immune response proteins
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- Regulation of NF-kappa B signaling
- PKR-mediated signaling
- SLC15A4:TASL-dependent IRF5 activation
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Modulation of host responses by IFN-stimulated genes
|
|
- Incontinentia pigmenti
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
- Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
|
|
IL6R |
interleukin 6 receptor |
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Interleukin-4 and Interleukin-13 signaling
- Transcriptional regulation of granulopoiesis
- Potential therapeutics for SARS
|
- Tocilizumab
- Sarilumab
- Satralizumab
|
|
|
INPPL1 |
inositol polyphosphate phosphatase like 1 |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Interleukin receptor SHC signaling
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|